ABOUT MIGRAINE

Migraine attacks are headaches of varying pain intensity often accompanied by nausea and sensitivity to light and sound. The SUMMIT Study is evaluating a new investigational medicine for the acute treatment of migraines.

ABOUT CLINICAL RESEARCH STUDIES

The main objective of a clinical research study is to learn as much as possible about the safety and effectiveness of potential new medications. These studies must be completed before a new treatment can be made available to the public. Every day, research uncovers new information about medical conditions and possible therapies. Right now, there are more than 300,000 clinical studies in progress all over the world.

This study is being conducted by:

PI NAME
SITE NAME
SITE ADDRESS

For more information:
(Insert Site Phone Number)

FOR PLACEMENT ONLY

studyURL.com

Migraines *don't* have to keep you from reaching new heights.

Consider joining the SUMMIT Study today.

summit study

A Clinical Research Study for those Who Suffer from Migraine

STUDY QUALIFICATIONS

You may be able to participate in the SUMMIT Study if you:

- Are 18 to 65 years of age
- Have had migraines for at least 1 year
- Have 2 to 8 migraine attacks each month
- Have less than 15 headache days each month

Additional study criteria will apply.

BENEFITS OF PARTICIPATION

Taking part in a clinical study has numerous benefits such as:

- Having access to investigative research treatments
- Helping others by contributing to medical research

If you choose to participate, you will receive all study-related medications and study-related care at no cost. Participants may be compensated and health insurance is not needed.

The images depicted contain models and are being used for illustrative purposes only.

STUDY DETAILS

The SUMMIT Study will last up to 3 months and will consist of 3 visits to the site. After establishing initial eligibility, the study participants will be able to use the investigational medicine (a powder administered into the nose) to potentially treat their next migraine attack.

Participants will also be asked to document the pain severity of their attacks, the presence of symptoms, and the impact on normal functioning over the 48-hour period after taking the investigational medicine.